A Prospective Study on the Diagnosis of Malignant Tumors With 18F-FGIn PET/CT

NCT07602569 | Recruiting

• 1 other identifier: IIT-2025021-02
• Study Type: observational
• Target: 110
• Locations: 1 country
• Sites: 1

Brief Summary

Glutamine is a crucial nutrient for cancer cell growth, and its metabolism is frequently dysregulated in malignancies. 18F-FGln is a PET tracer that targets this altered glutamine metabolism. However, there are currently limited studies on the diagnostic value of 18F-FGln PET/CT in various types of cancer. Therefore, this prospective study was conducted to investigate the value of 18F-FGln PET/CT in patients with various types of malignant tumors.

Conditions

Cancer (With or Without Metastasis)

Keywords

cancer

Outcome Measures

Primary Outcomes (2)

• SUVMAX

  Xingxiang's Chinese report system automatically delineates the areas of interest.

  Within one day after the PET/CT scan

• TBR

  Xingxiang's Chinese report system automatically delineates the areas of interest.

  Within one day after the PET/CT scan

Study Arms (1)

Patients with Malignant Tumors

Patients with suspected or histopathologically confirmed malignant tumors who underwent 18F-FGln PET/CT scan at the Affiliated Cancer Hospital \& Institute of Guangzhou Medical University

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

This study will include patients from the Affiliated Cancer Hospital \& Institute of Guangzhou Medical University who underwent an 18F-FGln PET/CT scan between October 2025 and January 2028 . Eligible participants are adult patients aged 18 to 70 years with suspected or histopathologically confirmed malignant tumors. Patients with non-malignant lesions, pregnant women, and those with incomplete medical records or missing histopathological reference standards will be excluded. Data will be collected by reviewing the institutional medical records and PET/CT imaging database.

You may qualify if:

• Patients undergoing tumor staging or evaluating treatment effect using 18F-FDG PET/CT or 18F-FGln PET/CT to determine the most appropriate treatment strategy
• Patients without other tumor history
• Patients with good compliance, providing informed consent, and able to follow the research protocol

You may not qualify if:

• pregnant or lactating patients or patients under 18 years old
• the subjects and their parents or legal representatives are unable or unwilling to provide written informed consent;
• patients with poor compliance, unable to tolerate or cooperate with PET/CT examinations.
• those who have undergone gastrointestinal barium meal examination within one week;
• other situations where the investigators consider it inappropriate for the subjects to participate in this clinical trial

Sponsors & Collaborators

• Affiliated Cancer Hospital & Institute of Guangzhou Medical University: lead

Study Sites (1)

Affiliated Cancer Hospital & Institute of Guangzhou Medical University

Guangzhou, China

RECRUITING

MeSH Terms

Conditions

Neoplasms

Central Study Contacts

Rusen Zhang

CONTACT

0086-13642328295; zhangrusen2015@163.com

HAO PENG

CONTACT

0086-13544443827; 1194171163@QQ.COM

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 6 Months
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Head of Nuclear Medicine Department

Study Record Dates

• First Submitted: May 16, 2026
• First Posted: May 22, 2026
• Study Start: October 20, 2025
• Primary Completion (Estimated): August 1, 2028
• Study Completion (Estimated): December 1, 2028
• Last Updated: May 22, 2026

Record last verified: 2025-08

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)